Risk of osteonecrosis of the jaw in cancer patients receiving Denosumab: a meta-analysis of seven randomized controlled trials

Abstract

Conclusions

The use of denosumab is associated with an increased risk of developing ONJ when compared with BP treatment or placebo, although the increased risk was not statistically significant between denosumab and BP treatment. Further studies are still needed to establish guidelines for the prevention and effective treatment of ONJ.